Breaking Down Icade SA Financial Health: Key Insights for Investors

Dive into Icade SA's latest financial heartbeat: revenue for the first nine months slid to €923.0 million, a -9.0% drop year‑on‑year as property development revenue fell to €650.9 million and gross rental income to €263.2 million, yet leasing momentum signed or renewed ~166,000 m² and occupancy for prime offices and light industrials rose to 88.8% and 90.4%; profitability showed contrasts with H1 EBITDA up to €144.8 million and an operating fair‑value change of -€200.5 million, while balance‑sheet strength is underscored by €500 million green bond issuance in May 2025, cash and short‑term investments of €1.1 billion, total equity of €3.9 billion versus €1.1 billion debt (debt/equity 29%) and NAV NTA of €56.6 per share, supporting management's maintained full‑year guidance of Group NCCF per share at €3.40-€3.60 even as LTV sits at 38.1% and pockets of risk persist around the Icade Santé disposal, a BBB downgrade and subdued market conditions-read on to unpack what these figures mean for investors.

Icade SA (ICAD.PA) - Revenue Analysis

Total IFRS consolidated revenue for the first nine months of 2025 was €923.0 million, representing a 9.0% decline versus the same period in 2024. The decline reflects weakness across both rental operations and property development.

• Gross rental income: €263.2 million (down 6.0%; like-for-like -4.8%)
• Property development revenue: €650.9 million (down 10.0%)
• Group Net Current Cash Flow (NCCF) per share full-year guidance: €3.40-€3.60 (maintained)

Operational notes:

• Leasing activity remained robust with approximately 166,000 m² signed or renewed during the period, supporting cash flow resilience despite revenue declines.
• Occupancy improvements concentrated in well-positioned office assets (88.8%) and light industrial portfolio (90.4%), indicating selective strength in high-quality assets.

Contextual link: Mission Statement, Vision, & Core Values (2026) of Icade SA.

Icade SA (ICAD.PA) Profitability Metrics

• EBITDA: €144.8m in H1 2025 vs. €85.0m in H1 2024 - a substantial year-over-year increase.
• Change in fair value of investment properties (included in operating profit): -€200.5m in H1 2025 vs. -€268.5m in H1 2024.
• Net finance expense: -€21.5m in H1 2025 vs. -€6.7m in H1 2024, driven by lower short‑term investment income and reduced dividends from the Healthcare business.
• Group Net Current Cash Flow (NCCF): €2.03 per share in H1 2025, of which €1.44 per share originated from strategic operations.
• EPRA net initial yield: improved to 5.3% in H1 2025 from 5.2% in H1 2024.
• Property Development operating margin: 2.3% in H1 2025 vs. -3.1% in H1 2024.

• Higher EBITDA reflects stronger cash-generating operations and portfolio management actions.
• Smaller negative revaluation impact on investment properties reduced operating profit pressure relative to H1 2024.
• Rising net finance expense warrants monitoring of investment income and Healthcare dividend streams.

Icade SA (ICAD.PA) - Debt vs. Equity Structure

• Total shareholder equity: €3.9 billion (30 Jun 2025)
• Total debt: €1.1 billion (30 Jun 2025)
• Debt-to-equity ratio: 29%
• Total assets: €10.1 billion
• Total liabilities: €6.2 billion
• Cash & short-term investments: €1.1 billion

• Leverage profile: with a 29% debt-to-equity ratio and €1.1bn of debt against €3.9bn equity, structural leverage is low relative to peers in REIT/real estate investment trusts.
• Liquidity: €1.1bn in cash and short-term investments provides near-term flexibility for refinancing, capex, or opportunistic acquisitions.
• Funding strategy: the €500m green bond (10y, 4.375%) in May 2025 diversifies maturities and supports ESG-linked financing.
• Coverage metrics: strong EBIT-driven interest coverage of 15.4x (and a company-reported coverage of 7.4x), indicating comfortable ability to service interest under current earnings.
• Asset-backed safety: an LTV of 38.1% denotes conservative mortgage/loan utilization against property values.

Icade SA (ICAD.PA) Liquidity and Solvency

• Net liquidity available (net of NEU CP): €2.8 billion versus gross debt of €4.6 billion.
• Liquidity composition: €1.0 billion cash (net of bank overdrafts) and €1.8 billion undrawn credit lines.
• Debt coverage horizon: committed liquidity positioned to cover debt payments through 2029.

• Arranged €290 million in revolving credit facilities (RCFs): €100 million to refinance facilities maturing in 2026 and €190 million of new financing.
• Issued a €500 million green bond in May 2025; the bond was three times oversubscribed and priced with a 197-basis-point spread.
• Average maturity of newly arranged credit facilities: 6 years.

Icade SA (ICAD.PA) Valuation Analysis

Icade's recent reporting and financing activity provide clear markers for valuation and capital structure assessment. Key market-driven metrics show marginal yield improvement, strong net asset backing per share and a solid leverage/coverage profile that supports the group's investment-grade positioning.

• EPRA net initial yield (NIY): 5.3% (up from 5.2%).
• NAV / NTA: €56.6 per share.
• Property Development operating margin: 2.3% (improved from -3.1% in H1 2024).
• Loan-to-Value (LTV): 38.1%.
• Interest coverage ratio: 7.4x.
• Green bond (May 2025): issued with a 197 bps spread on favorable terms.
• Average maturity of new credit facilities: 6 years.

Valuation implications and investor considerations:

• NAV of €56.6 provides a concrete reference for share valuation and potential discount/premium analysis versus market price.
• EPRA NIY at 5.3% signals slightly improved income yield on the portfolio; supports income-oriented valuation frameworks.
• Improved Property Development margin (2.3%) reduces project-level risk and increases development contribution to value.
• LTV at 38.1% and interest cover of 7.4x indicate ample headroom for leverage and resilience to rate shocks.
• Long average maturity (6 years) on new facilities and a well-placed green bond (197 bps spread) improve refinancing risk profile and lower near-term funding risk.

For deeper context on Icade's strategic positioning and business model, see: Icade SA: History, Ownership, Mission, How It Works & Makes Money

Icade SA (ICAD.PA) Risk Factors

Icade SA faces a concentrated set of near-term and structural risks that bear directly on cash flow visibility, balance-sheet metrics and valuation multiples. Several of these risks are linked to the pending disposal of its healthcare platform, broader market conditions in French real estate, and macro-financial headwinds.

• Disposal uncertainty: Præmia REIM holds options to acquire Icade's remaining stake in Icade Santé; these options expire in mid-2025, creating execution and timing risk for a material asset sale.
• Credit pressure: S&P lowered Icade's issuer credit rating from BBB+ to BBB in November 2024, explicitly citing lack of progress on the Icade Santé disposal.
• Sector headwinds: weaker economic activity and the phase-out of certain tax incentive schemes are weighing on transaction volumes and development pipelines.
• Macroeconomic environment: persistent institutional instability in France, elevated sovereign bond yields and slowing but still-positive inflation complicate financing and valuation dynamics.

Operational and financial impacts observed and expected:

• Limited revenue growth: 2024 saw muted top-line expansion driven by tenant departures and a slowdown in commercial development activity-management signaled revenue growth in the low single digits (c. +1-3% year-on-year) rather than previous mid-single-digit targets.
• Occupancy and leasing: tenant departures in 2024 increased vacancy and pushed up re-letting and incentive costs; market reports indicate vacancy expansion of roughly c.100-200 basis points in core office portfolios during the year.
• Financing costs: higher sovereign yields (French OAT 10y averaged c.3-4% through 2024) elevated borrowing costs and tightened margins on new development financing.
• Credit metrics: the S&P downgrade reflects stress on leverage and liquidity ratios until the Icade Santé transaction is crystallized; rating action increases cost of capital and may limit covenant flexibility.

For investors assessing Icade SA, the interaction of these risks determines the near‑term path for leverage, dividend capacity and NAV realization. Additional context on the company's history, ownership and business model is available here: Icade SA: History, Ownership, Mission, How It Works & Makes Money

Icade SA (ICAD.PA) - Growth Opportunities

• Completed/secured disposals totaling approximately €430 million: €210 million in healthcare assets and €220 million in mature or non‑strategic properties.
• Praemia Healthcare stake reduced from 22.52% (31/12/2024) to 21.61% (30/06/2025), reflecting continued healthcare portfolio rotation.
• Arranged revolving credit facilities to preload liquidity ahead of upcoming debt maturities and smooth refinancing risk.
• Issued green bonds to diversify funding sources and target sustainability‑linked investors.
• Pursuing asset rotation and portfolio diversification to mitigate market and concentration risks across office, healthcare and development exposures.
• Maintaining full‑year 2025 guidance: Group Net Current Cash Flow (NCCF) per share projected between €3.40 and €3.60.

• Investor implications: disposal proceeds and liquidity actions reduce refinance pressure, support dividend/cash‑flow targets tied to the NCCF guidance, and improve balance‑sheet optionality for selective accretive investments or development projects.
• Watch items: pace of asset disposals, final use of disposal proceeds (debt paydown vs. redeployment), and execution of green bond terms versus market expectations.